Primecap Management Co. CA Acquires 1,147,291 Shares of Edwards Lifesciences Corporation $EW

Primecap Management Co. CA raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 49.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,446,891 shares of the medical research company’s stock after purchasing an additional 1,147,291 shares during the quarter. Primecap Management Co. CA owned 0.59% of Edwards Lifesciences worth $269,581,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Nuveen LLC bought a new position in shares of Edwards Lifesciences during the first quarter worth approximately $330,881,000. Jennison Associates LLC raised its holdings in Edwards Lifesciences by 15.7% in the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock valued at $912,788,000 after buying an additional 1,584,958 shares during the last quarter. Mirova US LLC lifted its holdings in Edwards Lifesciences by 56.2% during the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after buying an additional 1,054,301 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Edwards Lifesciences during the 2nd quarter worth approximately $67,832,000. Finally, Woodline Partners LP raised its stake in Edwards Lifesciences by 7,805.0% during the first quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock worth $59,822,000 after buying an additional 814,917 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,314,725.84. The trade was a 24.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on EW shares. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Tuesday, July 29th. National Bankshares set a $92.00 target price on shares of Edwards Lifesciences in a report on Friday, October 31st. Daiwa America upgraded Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Finally, Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $91.39.

Edwards Lifesciences Trading Down 0.7%

Shares of NYSE EW opened at $84.13 on Wednesday. The company has a market cap of $48.82 billion, a PE ratio of 12.11, a P/E/G ratio of 3.97 and a beta of 1.03. The firm’s 50 day moving average price is $78.37 and its 200-day moving average price is $77.88. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period last year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.